Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PNMT | P11086 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LOX | P28300 | 1/20 | 0.43 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29467979 | 1.00 | CYP3A4 (0.71) | CYP3A4TSHRCSNK2A1ALDH1A1MAPK1 | |
| SCHEMBL30097830 | 0.83 | CYP3A4 (1.00) | CYP3A4TSHRALDH1A1MAPK1PNMT | |
| SCHEMBL43509 | 0.83 | CYP3A4 (1.00) | CYP3A4TSHRALDH1A1MAPK1PNMT | |
| SCHEMBL1170188 | 0.83 | CYP3A4 (0.74) | CYP3A4TSHRALDH1A1MAPK1PNMT | |
| SCHEMBL2735049 | 0.82 | TAAR1 (0.69) | CYP3A4TSHRALDH1A1MAPK1PNMT | |
| SCHEMBL638305 | 0.81 | TP53 (0.52) | CYP3A4TSHRCSNK2A1PNMTTAAR1 | |
| SCHEMBL8765734 | 0.81 | CYP3A4 (0.95) | CYP3A4TSHRALDH1A1MAPK1PNMT | |
| Ammonia Solution, Strong SCHEMBL9140534 | 0.81 | CYP3A4 (0.95) | CYP3A4TSHRALDH1A1MAPK1PNMT | |
| Hydrochloric Acid SCHEMBL1467765 | 0.80 | TAAR1 (0.67) | CYP3A4TSHRALDH1A1MAPK1PNMT | |
| SCHEMBL112200 | 0.80 | PNMT (0.67) | CSNK2A1PNMTTAAR1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101203244-A | Compositions of rennin inhibitor and insulin secernent or insulin sensitizer | NOVARTIS AG (CH) | 2008-06-18 | — | — | CN | claimed |
| CN-101163504-A | Combination therapy | XENON PHARMACEUTICALS INC (CA) | 2008-04-16 | — | — | CN | claimed |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11970497-B2 | Tricyclic AKR1C3 dependent KARS inhibitors | NOVARTIS AG (CH) | 2024-04-30 | — | — | US | disclosed |
| EP-4349839-A2 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| EP-4013500-B1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20220315582-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4013500-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| CN-114206870-A | Tricyclic AKR1C3 dependent KARS inhibitors | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021005586-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2021-01-14 | — | — | WO | disclosed |
| US-4282135-A | Aminoplast dispersions and polyurethanes prepared therefrom | BAYER AKTIENGESELLSCHAFT (DE) | 1981-08-04 | — | — | US | disclosed |
| US-4225481-A | Aminoplast dispersions and polyurethanes prepared therefrom | BAYER AKTIENGESELLSCHAFT (DE) | 1980-09-30 | — | — | US | disclosed |
| US-4217272-A | DYEING CELLULOSIC FIBERS | STERLING DRUG INC. (US) | 1980-08-12 | — | — | US | disclosed |
| US-4160754-A | Stable polymer gels | BAYER AKTIENGESELLSCHAFT (DE) | 1979-07-10 | — | — | US | disclosed |
| US-4153598-A | Monoazo and diazo colorants from aminoalkylanilines and bis(aminoalkyl)anilines | STERLING DRUG INC. (US) | 1979-05-08 | — | — | US | disclosed |
| US-4122049-A | Process for the production of polyurethane foam | BAYER AKTIENGESELLSCHAFT (DE) | 1978-10-24 | — | — | US | disclosed |
| US-4028310-A | REACTING POLYISOCYANATES WITH DIAMINES, COATINGS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-06-07 | — | — | US | disclosed |
| US-4028306-A | COATINGS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-06-07 | — | — | US | disclosed |
| US-3931112-A | POLYURETHANE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315582-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | CYP3A4 141/4885TSHR 3665/4885CSNK2A1 1091/4885 |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | CYP3A4 141/4885TSHR 3665/4885CSNK2A1 1091/4885 |
| US-11970497-B2 | Tricyclic AKR1C3 dependent KARS inhibitors | AKR1C2, AKR1B1, AKR1C1 | CYP3A4 141/4885TSHR 3665/4885CSNK2A1 1091/4885 |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | CYP3A4 141/4885TSHR 3665/4885CSNK2A1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.